PHARMACIA AND UPJOHN FDA Approval NDA 021132

NDA 021132

PHARMACIA AND UPJOHN

FDA Drug Application

Application #021132

Documents

Letter2004-07-01
Letter2004-06-25
Letter2005-05-17
Letter2005-11-08
Letter2008-06-24
Letter2010-07-23
Letter2013-05-07
Letter2012-02-15
Letter2015-06-10
Label2003-04-07
Label2003-04-07
Label2004-06-25
Label2013-05-09
Label2015-06-10
Review2005-07-11
Letter2000-04-18
Letter2004-07-01
Letter2003-07-28
Letter2004-01-14
Letter2005-02-11
Letter2005-05-17
Letter2007-05-01
Letter2008-06-24
Letter2010-01-26
Letter2013-05-07
Letter2014-01-28
Label2000-04-18
Label2005-05-17
Label2005-05-17
Label2007-05-01
Label2008-06-26
Label2009-12-11
Label2010-07-19
Label2013-05-09
Label2012-02-14
Label2014-01-27
Review2000-04-18
Review2014-07-07
Letter2017-07-14
Label2017-07-14
Label2018-02-02
Letter2018-02-02
Label2020-08-06
Label2020-08-06
Letter2020-08-06
Letter2020-08-06
Label2021-07-20
Letter2021-09-02
Label2021-09-13
Letter2021-10-27
Label2021-10-27

Application Sponsors

NDA 021132PHARMACIA AND UPJOHN

Marketing Status

Prescription001

Application Products

001FOR SUSPENSION;ORAL100MG/5ML1ZYVOXLINEZOLID

FDA Submissions

TYPE 3; Type 3 - New Dosage FormORIG1AP2000-04-18PRIORITY
LABELING; LabelingSUPPL2AP2002-12-19STANDARD
EFFICACY; EfficacySUPPL3AP2002-12-19PRIORITY
EFFICACY; EfficacySUPPL4AP2003-07-22STANDARD
LABELING; LabelingSUPPL5AP2004-01-05STANDARD
EFFICACY; EfficacySUPPL6AP2004-06-23PRIORITY
LABELING; LabelingSUPPL7AP2005-02-10STANDARD
LABELING; LabelingSUPPL8AP2005-05-12STANDARD
EFFICACY; EfficacySUPPL9AP2005-05-12PRIORITY
LABELING; LabelingSUPPL10AP2005-11-02STANDARD
LABELING; LabelingSUPPL12AP2007-04-26STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL13AP2007-03-26PRIORITY
LABELING; LabelingSUPPL14AP2008-06-20STANDARD
LABELING; LabelingSUPPL15AP2008-06-20STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL16AP2007-09-18PRIORITY
LABELING; LabelingSUPPL18AP2009-12-08STANDARD
LABELING; LabelingSUPPL21AP2010-07-16UNKNOWN
LABELING; LabelingSUPPL22AP2013-05-03STANDARD
LABELING; LabelingSUPPL23AP2013-05-03STANDARD
LABELING; LabelingSUPPL27AP2012-02-13STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL30AP2013-10-09PRIORITY
LABELING; LabelingSUPPL31AP2014-01-24STANDARD
MANUF (CMC); Manufacturing (CMC)SUPPL32AP2014-07-28PRIORITY
LABELING; LabelingSUPPL33AP2017-07-13STANDARD
LABELING; LabelingSUPPL34AP2015-06-05STANDARD Please see www.fda.gov/STIC for labeling requirements on susceptibility test interpretive criteria for systemic antibacterial and antifungal drugs.
LABELING; LabelingSUPPL35AP2018-02-01STANDARD
LABELING; LabelingSUPPL38AP2020-08-05STANDARD
LABELING; LabelingSUPPL39AP2020-08-05STANDARD
LABELING; LabelingSUPPL40AP2021-07-16STANDARD
LABELING; LabelingSUPPL41AP2021-09-01STANDARD
LABELING; LabelingSUPPL42AP2021-10-26STANDARD

Submissions Property Types

SUPPL5Null9
SUPPL9Null8
SUPPL13Null0
SUPPL16Null0
SUPPL18Null7
SUPPL21Null7
SUPPL22Null7
SUPPL23Null15
SUPPL27Null6
SUPPL30Null0
SUPPL31Null15
SUPPL32Null0
SUPPL33Null6
SUPPL34Null6
SUPPL35Null7
SUPPL38Null6
SUPPL39Null6
SUPPL40Null7
SUPPL41Null15
SUPPL42Null6

TE Codes

001PrescriptionAB

CDER Filings

PFIZER
cder:Array
(
    [0] => Array
        (
            [ApplNo] => 21132
            [companyName] => PFIZER
            [docInserts] => ["",""]
            [products] => [{"drugName":"ZYVOX","activeIngredients":"LINEZOLID","strength":"100MG\/5ML","dosageForm":"FOR SUSPENSION;ORAL","marketingStatus":"Prescription","te":"","rld":"Yes","rs":"Yes"}]
            [labels] => [{"actionDate":"10\/26\/2021","submission":"SUPPL-42","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/021130s043,021131s039,021132s042lbl.pdf\"}]","notes":""},{"actionDate":"09\/01\/2021","submission":"SUPPL-41","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/021130s042,021131s038,021132s041lbl.pdf\"}]","notes":""},{"actionDate":"07\/16\/2021","submission":"SUPPL-40","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2021\\\/021130s041,021131s037,021132s040lbl.pdf\"}]","notes":""},{"actionDate":"08\/05\/2020","submission":"SUPPL-39","supplementCategories":"Labeling-Container\/Carton Labels","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/021130s039s040,021131s034s035,021132s038s039lbl.pdf\"}]","notes":""},{"actionDate":"08\/05\/2020","submission":"SUPPL-39","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/021130s039s040,021131s034s035,021132s038s039lbl.pdf\"}]","notes":""},{"actionDate":"08\/05\/2020","submission":"SUPPL-38","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2020\\\/021130s039s040,021131s034s035,021132s038s039lbl.pdf\"}]","notes":""},{"actionDate":"02\/01\/2018","submission":"SUPPL-35","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2018\\\/021130s037,021131s030,021132s035lbl.pdf\"}]","notes":""},{"actionDate":"07\/13\/2017","submission":"SUPPL-33","supplementCategories":"Labeling-Container\/Carton Labels","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/021130Origs034,021131Orig1s028,021132Orig1s033lbl.pdf\"}]","notes":""},{"actionDate":"07\/13\/2017","submission":"SUPPL-33","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2017\\\/021130Origs034,021131Orig1s028,021132Orig1s033lbl.pdf\"}]","notes":""},{"actionDate":"06\/05\/2015","submission":"SUPPL-34","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2015\\\/021130s030,021131s029,021132s034lbl.pdf\"}]","notes":"Please see"},{"actionDate":"01\/24\/2014","submission":"SUPPL-31","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2014\\\/021130s032,021131s026,021132s031lbl.pdf\"}]","notes":""},{"actionDate":"05\/03\/2013","submission":"SUPPL-23","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/021130s023s024,021131s021s022,021132s022s023lbl.pdf\"}]","notes":""},{"actionDate":"05\/03\/2013","submission":"SUPPL-22","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2013\\\/021130s023s024,021131s021s022,021132s022s023lbl.pdf\"}]","notes":""},{"actionDate":"02\/13\/2012","submission":"SUPPL-27","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2012\\\/021132s027lbl.pdf\"}]","notes":""},{"actionDate":"07\/16\/2010","submission":"SUPPL-21","supplementCategories":"Labeling-Package Insert","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2010\\\/021132s021lbl.pdf\"}]","notes":""},{"actionDate":"12\/08\/2009","submission":"SUPPL-18","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2009\\\/021130s020,021131s017,021132s018lbl.pdf\"}]","notes":""},{"actionDate":"06\/20\/2008","submission":"SUPPL-14","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2008\\\/021130s016,s017,021131s013,s014,021132s014,s015ltr.pdf\"}]","notes":""},{"actionDate":"04\/26\/2007","submission":"SUPPL-12","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2007\\\/021130s012,021131s012,021132s012lbl.pdf\"}]","notes":""},{"actionDate":"05\/12\/2005","submission":"SUPPL-9","supplementCategories":"Efficacy-Labeling Change With Clinical Data","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2005\\\/021130s008,009,021131s009,010,021132s008,009lbl.pdf\"}]","notes":""},{"actionDate":"05\/12\/2005","submission":"SUPPL-8","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2005\\\/021130s008,009,021131s009,010,021132s008,009lbl.pdf\"}]","notes":""},{"actionDate":"06\/23\/2004","submission":"SUPPL-6","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2004\\\/21130se5-006,21131se5-007,21132se5-006_zyvox_lbl.pdf\"}]","notes":""},{"actionDate":"12\/19\/2002","submission":"SUPPL-3","supplementCategories":"Efficacy-New Patient Population","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21132se5-003,21131se5-003,21130se5-003_zyvox_lbl.pdf\"}]","notes":""},{"actionDate":"12\/19\/2002","submission":"SUPPL-2","supplementCategories":"Labeling","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2002\\\/21130slr002,21131slr002,21132slr002_zyvox_lbl.pdf\"}]","notes":""},{"actionDate":"04\/18\/2000","submission":"ORIG-1","supplementCategories":"Approval","inserts":"[{\"name\":\"Label (PDF)\",\"url\":\"https:\\\/\\\/www.accessdata.fda.gov\\\/drugsatfda_docs\\\/label\\\/2000\\\/21130lbl.pdf\"}]","notes":""}]
            [originalApprovals] => [{"actionDate":"ZYVOX","submission":"LINEZOLID","actionType":"100MG\/5ML","submissionClassification":"FOR SUSPENSION;ORAL","reviewPriority":"Prescription","inserts":"[]","notes":">Yes"}]
            [supplements] => 
            [actionDate] => 2021-10-26
        )

)

© 2024 FDA.report
This site is not affiliated with or endorsed by the FDA.